MYOS RENS Announces Distribution and Co-Marketing Agreement with KVP International, a Leading Distributor of Veterinary Rehabilitation Products

CEDAR KNOLLS, N.J., March 10, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin^®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that it has entered into an agreement with KVP International, Inc. ("KVP") (www.kvpvet.com), a leading supplier of innovative products for the veterinary rehabilitation market such as surgical supplies, recovery collars and braces. 

KVP will distribute, consult, and co-market with MYOS for its MYOS Canine Muscle Formula^®, Regular and Vet Strength (collectively, "MYOS Canine"), an advanced nutrition product that has been clinically shown to increase muscle mass, prevent atrophy of disuse and improve recovery from injury and surgery. 

"KVP is a leading supplier of high-quality products for the animal rehabilitation market," stated Joseph Mannello, CEO of MYOS RENS Technology. "Some of their products such as Saf-T-Shield™ animal recovery collars and KONG^® toys and treats are sought after by veterinarians and dog owners around the world.  We believe KVP's reach into over 10,000 veterinarian practices and buying groups will create new customers for MYOS' canine products," Mannello added. "We will also work with KVP to build our direct-to-consumer business working with their team and jointly marketing our products with theirs.  KVP's years of experience in these markets as well as their incredible customer relationships will help us to rapidly grow our business." 

"At KVP, we're constantly looking for new, innovative, and unique product offerings for our partners and customers," said Ken Bowman, CEO and President of KVP, "and MYOS Canine Muscle Formula^® represents just that– a clinically proven product that creates and extends quality of life for its users. MYOS Canine Muscle Formula is a great complimentary product to the work we're already doing in rehabilitation and recovery, and we're excited to build on our experience in the industry to help MYOS revolutionize this space."

In 2019, at the North American Veterinary Conference in Orlando, FL, MYOS released the results of the Kansas State University canine clinical study on dogs that consumed MYOS Canine Muscle Formula following tibial plateau leveling osteotomy (TPLO) surgery to repair tears of the cranial cruciate ligament (CCL).  After eight weeks, dogs who underwent the surgery and consumed MYOS Canine Muscle Formula experienced reduced muscle atrophy and improved recovery compared with dogs that received a macronutrient-matched placebo.  Since the study results were released, MYOS has initiated another clinical study at Kansas State University to examine the impact of MYOS Canine Muscle Formula on quality of life and activity in geriatric dogs.

In addition to the MYOS' distribution partnership with KVP, its products for the animal health market are available direct-to-consumer at www.myospet.com, Amazon.com, and Chewy.com.

About KVP INTERNATIONAL, INC.
Founded in 1964, KVP entered the veterinary marketplace with the introduction of its Saf-T-Shield™ Elizabethan Collar. Widely praised by veterinarians and their technicians as innovative, highly effective and a great value, the Saf-T-Shield™ Soft Pet Cloth Recovery Collar set the standard for each and every KVP product that would follow. More than 50 years later, KVP offers the world's largest selection of recovery collars– from mice to mastiffs.

As well as the world's largest selection of recovery collars, KVP has quality surgical supplies and highly effective patient care products. KVP proudly carries the full KONG^® catalog including the veterinary-exclusive KONG^® Blue™ as well as products from the well-loved brands FURminator^® and Nature's Miracle™.

About Myos Canine Muscle Formula^®
Myos Canine Muscle Formula (Regular and Veterinarian Strength) is an advanced veterinary health supplement to support muscle health in dogs, featuring Fortetropin^® as the active ingredient. Fortetropin is made through a patented process that maintains the vital nutrients of fertilized egg yolks to help build more lean muscle and decrease muscle loss.  For more information, please visit www.myospet.com.

About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle Company^®", is a Cedar Knolls, NJ-based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin^®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass and reduce muscle atrophy. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness. For more information, please visit www.myosrens.com. 

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the success of our products, including MYOS Canine Muscle Formula^®, Yolked^®, Physician Muscle Health Formula^®, Qurr^® and MYOS Enteral Nutrition Formula™, the success of our research and development, the results of the clinical evaluation of Fortetropin^® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, including its partnership with KVP discussed above, the ability to generate revenue and cash flow from sales of our products, the ability to increase our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with  the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email:  [email protected]

SOURCE MYOS RENS Technology

Related Links

http://www.myosrens.com